Cargando…
Telemedicine and intraductal papillary mucinous neoplasms: Analysis of a new follow-up strategy during COVID-19 outbreak
BACKGROUND: The Coronavirus pandemic outbreak in 2019 and the saturation of healthcare system led to an increased use of digital tools for surveillance. In this study we described our experience using telemedicine to follow-up on patients with intraductal papillary mucinous neoplasms during the COVI...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468315/ https://www.ncbi.nlm.nih.gov/pubmed/36272774 http://dx.doi.org/10.1016/j.surg.2022.09.005 |
_version_ | 1784788382062215168 |
---|---|
author | Farguell, J. Holguin, V. González, C. Gil, I. Arrocha, C. Landi, F. Vaquero, E. Gines, A. Fillat, C. Ausania, F. |
author_facet | Farguell, J. Holguin, V. González, C. Gil, I. Arrocha, C. Landi, F. Vaquero, E. Gines, A. Fillat, C. Ausania, F. |
author_sort | Farguell, J. |
collection | PubMed |
description | BACKGROUND: The Coronavirus pandemic outbreak in 2019 and the saturation of healthcare system led to an increased use of digital tools for surveillance. In this study we described our experience using telemedicine to follow-up on patients with intraductal papillary mucinous neoplasms during the COVID-19 era and analyze those factors associated to patients’ satisfaction. METHODS: This 1-year retrospective observational study enrolled patients with intraductal papillary mucinous neoplasms followed-up by telemedicine during COVID-19 outbreak. Patients with high-risk features needing on-site physical examination or declining remote follow-up were excluded. A 13-question survey was conducted; demographic, geographic, and employment information was collected. Univariate and multivariate analyses were performed to evaluate those factors associated to patients’ satisfaction. RESULTS: Out of 287, a total of 177 patients with intraductal papillary mucinous neoplasms were included: the mean age was 69 (44–87) years and the male/female ratio was 0.78. A total of 80 (45.2%) patients had previously experienced abdominal pain. Most patients (85.3%) were satisfied with telemedicine: at univariate analysis, age ≥70 years (P = .007), retirement (P = .001), and absence of previous abdominal pain (P = .05) were significantly associated with patient satisfaction. At multivariate analysis, the absence of previous abdominal pain was the only factor independently associated with patient satisfaction (odds ratio 5.964, 95% confidence interval 2.21–16.11, P < .001). CONCLUSION: Telemedicine allows a new follow-up strategy that can be used in selected patients with intraductal papillary mucinous neoplasms. The absence of previous abdominal pain is associated with patient satisfaction during follow-up. Further studies are needed to evaluate safety of remote follow-up in patients with intraductal papillary mucinous neoplasms. |
format | Online Article Text |
id | pubmed-9468315 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94683152022-09-13 Telemedicine and intraductal papillary mucinous neoplasms: Analysis of a new follow-up strategy during COVID-19 outbreak Farguell, J. Holguin, V. González, C. Gil, I. Arrocha, C. Landi, F. Vaquero, E. Gines, A. Fillat, C. Ausania, F. Surgery Covid-19 BACKGROUND: The Coronavirus pandemic outbreak in 2019 and the saturation of healthcare system led to an increased use of digital tools for surveillance. In this study we described our experience using telemedicine to follow-up on patients with intraductal papillary mucinous neoplasms during the COVID-19 era and analyze those factors associated to patients’ satisfaction. METHODS: This 1-year retrospective observational study enrolled patients with intraductal papillary mucinous neoplasms followed-up by telemedicine during COVID-19 outbreak. Patients with high-risk features needing on-site physical examination or declining remote follow-up were excluded. A 13-question survey was conducted; demographic, geographic, and employment information was collected. Univariate and multivariate analyses were performed to evaluate those factors associated to patients’ satisfaction. RESULTS: Out of 287, a total of 177 patients with intraductal papillary mucinous neoplasms were included: the mean age was 69 (44–87) years and the male/female ratio was 0.78. A total of 80 (45.2%) patients had previously experienced abdominal pain. Most patients (85.3%) were satisfied with telemedicine: at univariate analysis, age ≥70 years (P = .007), retirement (P = .001), and absence of previous abdominal pain (P = .05) were significantly associated with patient satisfaction. At multivariate analysis, the absence of previous abdominal pain was the only factor independently associated with patient satisfaction (odds ratio 5.964, 95% confidence interval 2.21–16.11, P < .001). CONCLUSION: Telemedicine allows a new follow-up strategy that can be used in selected patients with intraductal papillary mucinous neoplasms. The absence of previous abdominal pain is associated with patient satisfaction during follow-up. Further studies are needed to evaluate safety of remote follow-up in patients with intraductal papillary mucinous neoplasms. Elsevier Inc. 2022-12 2022-09-13 /pmc/articles/PMC9468315/ /pubmed/36272774 http://dx.doi.org/10.1016/j.surg.2022.09.005 Text en © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Covid-19 Farguell, J. Holguin, V. González, C. Gil, I. Arrocha, C. Landi, F. Vaquero, E. Gines, A. Fillat, C. Ausania, F. Telemedicine and intraductal papillary mucinous neoplasms: Analysis of a new follow-up strategy during COVID-19 outbreak |
title | Telemedicine and intraductal papillary mucinous neoplasms: Analysis of a new follow-up strategy during COVID-19 outbreak |
title_full | Telemedicine and intraductal papillary mucinous neoplasms: Analysis of a new follow-up strategy during COVID-19 outbreak |
title_fullStr | Telemedicine and intraductal papillary mucinous neoplasms: Analysis of a new follow-up strategy during COVID-19 outbreak |
title_full_unstemmed | Telemedicine and intraductal papillary mucinous neoplasms: Analysis of a new follow-up strategy during COVID-19 outbreak |
title_short | Telemedicine and intraductal papillary mucinous neoplasms: Analysis of a new follow-up strategy during COVID-19 outbreak |
title_sort | telemedicine and intraductal papillary mucinous neoplasms: analysis of a new follow-up strategy during covid-19 outbreak |
topic | Covid-19 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468315/ https://www.ncbi.nlm.nih.gov/pubmed/36272774 http://dx.doi.org/10.1016/j.surg.2022.09.005 |
work_keys_str_mv | AT farguellj telemedicineandintraductalpapillarymucinousneoplasmsanalysisofanewfollowupstrategyduringcovid19outbreak AT holguinv telemedicineandintraductalpapillarymucinousneoplasmsanalysisofanewfollowupstrategyduringcovid19outbreak AT gonzalezc telemedicineandintraductalpapillarymucinousneoplasmsanalysisofanewfollowupstrategyduringcovid19outbreak AT gili telemedicineandintraductalpapillarymucinousneoplasmsanalysisofanewfollowupstrategyduringcovid19outbreak AT arrochac telemedicineandintraductalpapillarymucinousneoplasmsanalysisofanewfollowupstrategyduringcovid19outbreak AT landif telemedicineandintraductalpapillarymucinousneoplasmsanalysisofanewfollowupstrategyduringcovid19outbreak AT vaqueroe telemedicineandintraductalpapillarymucinousneoplasmsanalysisofanewfollowupstrategyduringcovid19outbreak AT ginesa telemedicineandintraductalpapillarymucinousneoplasmsanalysisofanewfollowupstrategyduringcovid19outbreak AT fillatc telemedicineandintraductalpapillarymucinousneoplasmsanalysisofanewfollowupstrategyduringcovid19outbreak AT ausaniaf telemedicineandintraductalpapillarymucinousneoplasmsanalysisofanewfollowupstrategyduringcovid19outbreak |